J. G. M. Segalla

Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer

José Baselga, J. G. M. Segalla, Henri Roché et al. · Journal of Clinical Oncology · 2012 · 160 citations · Full text

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)

Aňa Lluch, Carlos H. Barrios, Laura Torrecillas et al. · Journal of Clinical Oncology · 2019 · 143 citations · Full text

Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: The AMAZONA retrospective cohort study

Sérgio D. Simon, José Bines, Gustavo Werutsky et al. · The Breast · 2019 · 112 citations

Breast Oncology, Cancer Epidemiology, Medicine +6

A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial

Gilberto de Castro, J. G. M. Segalla, Sérgio Jobim Azevedo et al. · European Journal of Cancer · 2017 · 52 citations

Nice Trial, Esophageal Cancer, Gastrointestinal Oncology +6

Randomized Phase II Study of Carboplatin and Paclitaxel With Either Linifanib or Placebo for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Suresh S. Ramalingam, Mikhail Shtivelband, Ross A. Soo et al. · Journal of Clinical Oncology · 2015 · 43 citations · Full text